BC2001试验中接受新辅助化疗后放(化)疗的肌层浸润性膀胱癌患者结局
BC2001试验中117例(33%)接受新辅助化疗的肌层浸润性膀胱癌患者随机接受放疗联合或不联合同步化疗。中位随访110个月,联合化疗组局部区域控制有改善趋势但未达统计学显著(aHR=0.64,95%CI 0.33-1.23,p=0.18),总生存无差异,生活质量无显著损害。
要点
- 新辅助化疗后行根治性放(化)疗可行,不影响根治性治疗实施。
- 同步化疗组局部区域控制有改善趋势但未达统计学显著。
- 同步化疗组3级及以上毒性有非显著增加,生活质量无损害。
核心结论
- 新辅助化疗不损害根治性放(化)疗的实施,同步化疗改善局部控制的获益与主试验一致但本亚组样本量小、检验效能不足。
研究设计与样本
- BC2001试验亚组分析,117例(33%)接受新辅助化疗的患者随机接受放疗联合(48%)或不联合(52%)同步化疗,2001年8月至2008年4月从英国28个中心招募。
主要发现
- 同步放化疗组3级及以上毒性发生率为33%,单纯放疗组为22%,差异无统计学意义(p=0.16)。
- 中位随访110个月(四分位距96-123),同步放化疗组局部区域控制改善但无统计学意义(aHR=0.64,95%CI 0.33-1.23,p=0.18)。
- 总生存无差异(aHR=0.95,95%CI 0.57-1.57,p=0.8)。
- 同步放化疗组与单纯放疗组生活质量无显著损害。
- 74%的患者接受吉西他滨联合顺铂或卡铂方案。
临床怎么用
- 肌层浸润性膀胱癌患者接受新辅助化疗后仍可安全实施根治性放(化)疗。
- 同步放化疗虽毒性有非显著增加,但生活质量无损害,可考虑用于局部控制。
局限性
- 亚组样本量小,检验效能不足。
- 毒性增加无统计学意义,需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: BC2001 demonstrated improved local control with the addition of chemotherapy to radiotherapy in 360 patients with muscle-invasive bladder cancer. OBJECTIVE: To establish whether such benefit remained in BC2001 patients who received prior neoadjuvant chemotherapy. DESIGN, SETTING, AND PARTICIPANTS: A total of 117 patients (33%) received neoadjuvant chemotherapy and were randomised to radiotherapy with (48%) or without (52%) concomitant chemotherapy. Patients were recruited between August 2001 and April 2008 from 28 UK centres. INTERVENTION: Platinum-based neoadjuvant chemotherapy, followed by radiotherapy with (cRT) or without (RT) synchronous 5-fluorouracil and mitomycin-C. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Toxicity, locoregional control (LRC), overall survival (OS), and quality of life (QoL) were measured. RESULTS AND LIMITATIONS: Of the patients, 74% received gemcitabine plus cisplatin or carboplatin. Compliance rates with full-dose radiotherapy were cRT 93% and RT 92%. An excess of grade ≥3 toxicities while on (chemo)radiation occurred for cRT 33% versus RT 22%, although nonstatistically significant (p = 0.16). With 110 mo median follow-up for survival (interquartile range 96-123), cRT showed improved LRC though not statistically significant (adjusted hazard ratio [aHR] = 0.64, 95% confidence interval [CI] 0.33-1.23, p = 0.18). No differences in OS (aHR = 0.95, 95% CI 0.57-1.57, p = 0.8) were observed. No significant detriment in QoL was observed between cRT and RT in this subgroup of patients. CONCLUSIONS: Neoadjuvant chemotherapy does not compromise the delivery of radical curative treatment. Although underpowered due to a small sample size, the benefit of chemoradiotherapy to improve local control in this group of patients receiving neoadjuvant chemotherapy is consistent with that observed in the main trial. Although a nonsignificant excess of toxicity was observed, there was no evidence of impaired QoL. PATIENT SUMMARY: Chemotherapy before radical chemo(radiotherapy) is feasible and well tolerated.
引用
- Hussain SA, Porta N, Hall E, et al. Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by (Chemo)radiotherapy in the BC2001 Trial. Eur Urol. 2020. PMID: 33293079. doi:10.1016/j.eururo.2020.11.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。